9 times out of 10 when someone avoids answering a question it means they do not know the answer. The other 10% know the answer, but are too arrogant to play another person's game. I suspect you are part of the latter group. You also talk in a way that makes me think you might work for BPTH. Your arrogance level is very high. Based on these facts, one could draw the conclusion that you are Peter Nielsen himself.
I invite the rest of the board to assume this guy is PN and let him know what you think.
Just in case you are part of the 90% who don't know anything, let me explain:
Cell walls are semi-permeable lipid membranes that allow certain molecules to pass into the cell, such as glucose for metabolism or amino acids for protein synthesis. BPTH uses liposomes because the outer lipid layer is compatible with the lipid cell wall allowing the contents of the liposome to pass through the cell wall. BPTH is not the first or only company to use this method, but they are first to create a liposomal delivery system that has a neutral charge. Past efforts to deliver antisense therapies using liposomes failed because they were positively or negatively charged, which caused toxic side effects in patients. BPTH solved this problem (or more accurately MD Anderson solved this problem and then licensed the tech to BPTH).
The high uptake levels and no toxicity makes BPTH's delivery system very exciting and opens up many applications even beyond cancer therapy. Without a neutrally charged liposomal delivery system, other companies will not be able to replicate BPTH's technology.
Ionis Pharm. uses antisense technology but struggles with toxic side effects. Despite the toxicity, they have partnerships with major pharma companies and a much higher market cap than BPTH.
Comparing Ionis to BPTH, should lead one to the conclusion that BPTH has the more promising antisense technology, but the market disagrees. The science is on our side. So what is wrong? Oh yeah, BPTH is poorly managed.
Despite weak management we continue to hold our shares and even buy more at opportune times, because we understand the disruptive nature of this technology and the promise of better, safer, more effective treatments for those suffering from cancer and other diseases. I hope a partnership with a stronger company can be made soon so BPTH's technology might actually see the light of day.
